Centrum Neurologii Krzysztof Selmaj

Lodz 93-121

0 studies enrolling now · 14 studies all time

What they study most

Multiple Sclerosis, Multiple Sclerosis, Primary Progressive, Multiple Sclerosis, Relapsing-Remitting, Primary Progressive Multiple Sclerosis, Progressive Multiple Sclerosis (PMS), Relapsing Multiple Sclerosis, Relapsing-remitting Multiple Sclerosis (RRMS)

Studies at this site

• A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis — Running, not enrolling
• Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) — Running, not enrolling
• A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis (PPMS) — Running, not enrolling
• A Study to Evaluate Ocrelizumab Treatment in Participants With Progressive Multiple Sclerosis — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Teriflunomide in Relapsing Multiple Sclerosis (RMS) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Ocrelizumab in Adults With Primary Progressive Multiple Sclerosis — Running, not enrolling
• A Phase III, Non-Inferiority, Randomized, Open-Label, Parallel Group, Multicenter Study To Investigate The Pharmacokinetics, Pharmacodynamics, Safety And Radiological And Clinical Effects Of Subcutaneous Ocrelizumab Versus Intravenous Ocrelizumab In Patients With Multiple Sclerosis — Completed
• Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS) — Stopped early
• A Study of Ocrelizumab in Comparison With Interferon Beta-1a (Rebif) in Participants With Relapsing Multiple Sclerosis — Completed
• Efficacy and Safety Study of Ozanimod in Relapsing Multiple Sclerosis — Completed